Investors Buy High Volume of Genmab A/S Call Options (NASDAQ:GMAB)

Genmab A/S Sponsored ADR (NASDAQ:GMAB) saw unusually large options trading activity on Wednesday. Stock traders purchased 4,002 call options on the company. This is an increase of 169% compared to the average daily volume of 1,487 call options.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC lifted its stake in shares of Genmab A/S by 124.9% in the second quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company’s stock worth $44,000 after buying an additional 1,174 shares in the last quarter. Sei Investments Co. increased its position in shares of Genmab A/S by 4.2% during the second quarter. Sei Investments Co. now owns 62,111 shares of the company’s stock valued at $1,283,000 after acquiring an additional 2,496 shares in the last quarter. Squarepoint Ops LLC increased its position in shares of Genmab A/S by 636.3% during the second quarter. Squarepoint Ops LLC now owns 94,233 shares of the company’s stock valued at $1,947,000 after acquiring an additional 81,434 shares in the last quarter. Quantinno Capital Management LP raised its holdings in Genmab A/S by 64.9% in the 2nd quarter. Quantinno Capital Management LP now owns 158,132 shares of the company’s stock worth $3,267,000 after acquiring an additional 62,226 shares during the last quarter. Finally, Raymond James Financial Inc. raised its holdings in Genmab A/S by 48.1% in the 2nd quarter. Raymond James Financial Inc. now owns 31,146 shares of the company’s stock worth $643,000 after acquiring an additional 10,113 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

GMAB has been the topic of several research reports. HC Wainwright lifted their price objective on Genmab A/S from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Truist Financial initiated coverage on Genmab A/S in a research report on Wednesday, May 27th. They issued a “buy” rating and a $40.00 target price for the company. Weiss Ratings raised Genmab A/S from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. TD Cowen upgraded Genmab A/S from a “hold” rating to a “buy” rating and raised their target price for the company from $32.00 to $43.00 in a research note on Wednesday, July 22nd. Finally, Guggenheim lifted their price target on Genmab A/S from $40.00 to $42.00 and gave the company a “buy” rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $39.50.

Genmab A/S Trading Down 1.8%

Genmab A/S stock opened at $33.75 on Thursday. Genmab A/S has a 12 month low of $23.62 and a 12 month high of $35.43. The company has a market capitalization of $21.04 billion, a price-to-earnings ratio of 26.58, a price-to-earnings-growth ratio of 2.04 and a beta of 0.83. The business’s fifty day simple moving average is $29.35 and its two-hundred day simple moving average is $27.96. The company has a current ratio of 2.46, a quick ratio of 2.44 and a debt-to-equity ratio of 0.81.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.17. The firm had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.12 billion. Genmab A/S had a return on equity of 14.89% and a net margin of 19.08%. As a group, equities analysts predict that Genmab A/S will post 1.17 earnings per share for the current fiscal year.

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.